M Ingelman-Sundberg

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
    M Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics J 5:6-13. 2005
  2. ncbi Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase
    M Oscarson
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    FEBS Lett 438:201-5. 1998
  3. pmc Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs
    S D Lytton
    Division of Molecular Toxicology, Institute for Environmental Medicine, Karolinska Institute, and Department of Paediatrics, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Clin Exp Immunol 127:293-302. 2002
  4. pmc Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
    I Johansson
    Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
    Proc Natl Acad Sci U S A 90:11825-9. 1993
  5. ncbi Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43
    A Westlind
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, SE 171 77, Sweden
    Biochem Biophys Res Commun 281:1349-55. 2001
  6. ncbi Benzene metabolism by ethanol-, acetone-, and benzene-inducible cytochrome P-450 (IIE1) in rat and rabbit liver microsomes
    I Johansson
    Department of Physiological Chemistry, Karolinska Institute, Stockholm, Sweden
    Cancer Res 48:5387-90. 1988
  7. pmc Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population
    M G Scordo
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Br J Clin Pharmacol 52:447-50. 2001
  8. ncbi Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity
    M Pitarque
    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, 171 77, Sweden
    Biochem Biophys Res Commun 284:455-60. 2001
  9. ncbi Centrilobular expression of ethanol-inducible cytochrome P-450 (IIE1) in rat liver
    M Ingelman-Sundberg
    Department of Physiological Chemistry, Karolinska Institute, Stockholm, Sweden
    Biochem Biophys Res Commun 157:55-60. 1988
  10. ncbi Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies
    I Johansson
    Department of Physiological Chemistry, Karolinska Institute, Stockholm, Sweden
    Biochemistry 27:1925-34. 1988

Collaborators

Detail Information

Publications47

  1. ncbi Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
    M Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics J 5:6-13. 2005
    ....
  2. ncbi Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase
    M Oscarson
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    FEBS Lett 438:201-5. 1998
    ..An allele frequency of 1-3% was observed in Finnish, Spanish, and Swedish populations, much lower than described previously...
  3. pmc Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs
    S D Lytton
    Division of Molecular Toxicology, Institute for Environmental Medicine, Karolinska Institute, and Department of Paediatrics, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Clin Exp Immunol 127:293-302. 2002
    ....
  4. pmc Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
    I Johansson
    Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
    Proc Natl Acad Sci U S A 90:11825-9. 1993
    ..Furthermore, the finding of a specific haplotype with two or more active CYP2D6 genes allows genotyping for ultrarapid drug metabolizers. This genotyping could be of predictive value for individualized and more efficient drug therapy...
  5. ncbi Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43
    A Westlind
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, SE 171 77, Sweden
    Biochem Biophys Res Commun 281:1349-55. 2001
    ..It is concluded that CYP3A43 mRNA is expressed mainly in liver and testis and that the protein would not contribute significantly to human drug metabolism...
  6. ncbi Benzene metabolism by ethanol-, acetone-, and benzene-inducible cytochrome P-450 (IIE1) in rat and rabbit liver microsomes
    I Johansson
    Department of Physiological Chemistry, Karolinska Institute, Stockholm, Sweden
    Cancer Res 48:5387-90. 1988
    ....
  7. pmc Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population
    M G Scordo
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Br J Clin Pharmacol 52:447-50. 2001
    ..The distribution of variant CYP2C9 alleles was therefore investigated in an Italian and an Ethiopian population...
  8. ncbi Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity
    M Pitarque
    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, 171 77, Sweden
    Biochem Biophys Res Commun 284:455-60. 2001
    ..It is concluded that the CYP2A6*9 allele might be one of the most common CYP2A6 variants in Caucasians that alters the levels of enzyme expression...
  9. ncbi Centrilobular expression of ethanol-inducible cytochrome P-450 (IIE1) in rat liver
    M Ingelman-Sundberg
    Department of Physiological Chemistry, Karolinska Institute, Stockholm, Sweden
    Biochem Biophys Res Commun 157:55-60. 1988
    ..The regiospecific expression and induction of P-450IIE1 may explain why several hepatotoxins, known to be metabolized by this isozyme, primarily damage the centrilobular region in the liver...
  10. ncbi Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies
    I Johansson
    Department of Physiological Chemistry, Karolinska Institute, Stockholm, Sweden
    Biochemistry 27:1925-34. 1988
    ..The results indicate that effects of ethanol, acetone, and/or starvation on drug and xenobiotic metabolism are caused by the induction of P-450 forms belonging to at least two gene subfamilies...
  11. ncbi Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients
    I Persson
    Institute of Environmental Medicine, Division of Molecular Toxicology, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 81:325-9. 1999
    ..An increased risk for lung cancer in subjects carrying the HYL*3 allele was observed and suggests that polymorphism in this gene might possibly be a susceptibility factor in the Chinese population...
  12. ncbi Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1)
    T Rylander
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Biochem Biophys Res Commun 281:529-35. 2001
    ..We conclude that CYP2S1 represents a novel abundantly expressed human P450 with potential importance for extrahepatic xenobiotic metabolism...
  13. ncbi Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane
    E P Neve
    Division of Molecular Toxicology, National Institute of Environmental Medicine, Karolinska Institutet, Box 210, S 171 77 Stockholm, Sweden
    J Biol Chem 275:17130-5. 2000
    ....
  14. ncbi Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism
    M Oscarson
    Division of Molecular Toxicology, National Institute of Environmental Medicine, Karolinska Institutet, Box 210, 171 77, Stockholm, Sweden
    FEBS Lett 460:321-7. 1999
    ..We conclude that molecular epidemiological studies concerning CYP2A6 require validated genotyping methods for accurate detection of all known defective CYP2A6 alleles...
  15. ncbi Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells
    M Backlund
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Eur J Biochem 261:66-71. 1999
    ..3- and 23-fold induction by omeprazole and TCDD, respectively. Thus, these data indicate that the benzimidazoles utilize the aryl hydrocarbon receptor-arnt-XRE-mediated signal-transduction pathway for induction of the CYP1A1 gene...
  16. ncbi Genetic polymorphism of human CYP2E1: characterization of two variant alleles
    Y Hu
    Department of Medical Biochemistry, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Mol Pharmacol 51:370-6. 1997
    ..We conclude that the human CYP2E1 gene is functionally surprisingly well conserved compared with other cytochrome P450 enzymes active in drug metabolism, which suggests an important endogenous function in humans...
  17. ncbi CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes
    M Hidestrand
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
    Drug Metab Dispos 29:1480-4. 2001
    ..The data strongly indicate that the high extent of interindividual variation seen in vivo for selegiline clearance is caused by the metabolism of the compound by the highly polymorphic CYP2B6 and CYP2C19...
  18. ncbi A stress-inducible rat liver endoplasmic reticulum protein, ERp29
    S Mkrtchian
    Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
    Eur J Biochem 251:304-13. 1998
    ..Taken together, these results suggest that ERp29 is a member of the stress-response machinery of the ER...
  19. ncbi Enzyme-specific transport of rat liver cytochrome P450 to the Golgi apparatus
    E P Neve
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
    Arch Biochem Biophys 333:459-65. 1996
    ..It is suggested that various forms of hepatic cytochrome P450 are transported to the plasma membrane through the Golgi apparatus in an enzyme-specific manner...
  20. ncbi Role of CYP2C9 polymorphism in losartan oxidation
    G Tybring
    Division of Clinical Pharmacology, Department of Medical Laboratory Sciences and Technology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Drug Metab Dispos 29:1051-6. 2001
    ..In summary, these in vitro results indicate that CYP2C9 is the major human P450 isoenzyme responsible for losartan oxidation and that the CYP2C9 genotype contributes to interindividual differences in losartan oxidation and activation...
  21. ncbi Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures
    E Eliasson
    Department of Physiological Chemistry, Karolinska Institute, Stockholm, Sweden
    Biochem Biophys Res Commun 150:436-43. 1988
    ..It is suggested that the ligand-bound form of P-450j in the hepatocytes is protected from degradation...
  22. ncbi Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity
    A Wennerholm
    Division of Clinical Pharmacology, Department of Medical Laboratory Sciences and Technology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Pharmacogenetics 11:417-27. 2001
    ..The results indicate the common existence in Tanzanians of a variant CYP2D6 form with different substrate specificity as compared to the wild-type form of the enzyme causing reduced capacity for debrisoquine metabolism...
  23. ncbi Functional polymorphism in the alcohol dehydrogenase 3 (ADH3) promoter
    J J Hedberg
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenetics 11:815-24. 2001
    ..These base pair exchanges may have an effect on the expression of the enzyme and thereby influence the capacity of certain individuals to metabolize formaldehyde...
  24. ncbi Genetic variability in susceptibility and response to toxicants
    M Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Box 210, 171 77, Stockholm, Sweden
    Toxicol Lett 120:259-68. 2001
    ..In the present contribution an overview is presented regarding our present knowledge about the polymorphism of phase I enzymes, with emphasis on xenobiotic metabolising CYPs and the importance for metabolic activation of xenobiotics...
  25. ncbi Functional consequences of polymorphism of xenobiotic metabolising enzymes
    M Ingelman-Sundberg
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
    Toxicol Lett 102:155-60. 1998
    ..In this overview the most important polymorphic enzymes are discussed and their consequences for drug metabolism, effective drug treatment and adverse effects of drugs are emphasised...
  26. ncbi Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype
    A Wennerholm
    Department of Medical Laboratory Sciences and Technology, Karolinska Institutet, Huddinge University Hospital, Sweden
    Pharmacogenetics 9:707-14. 1999
    ....
  27. ncbi Characterization and functional analysis of two common human cytochrome P450 1B1 variants
    R A McLellan
    Division of Molecular Toxicology, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Arch Biochem Biophys 378:175-81. 2000
    ..The combined results indicate that these two CYP1B1 variants show very similar properties with respect to catalytic activities and protein stability and do not alter CYP1B1 function...
  28. pmc Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase
    A Zhukov
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, S 171 77 Stockholm, Sweden
    Biochem J 340:453-8. 1999
    ....
  29. pmc Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene
    A Persson
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Mol Psychiatry 19:733-41. 2014
    ..Furthermore, CYP2C19 polymorphism may have a role in interindividual susceptibility for psychiatric disorders. ..
  30. doi Epigenomics and interindividual differences in drug response
    M Ivanov
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Clin Pharmacol Ther 92:727-36. 2012
    ....
  31. doi Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects
    S C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics J 13:1-11. 2013
    ....
  32. ncbi Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells
    M Backlund
    Division of Molecular Toxicology, Institute of Environmental Medicine and Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S 171 77 Stockholm, Sweden
    J Biol Chem 272:31755-63. 1997
    ..The data are consistent with a mechanism for OME-mediated induction of CYP1A1 that involves activation of the AhR complex via intracellular signal transduction systems and that is distinct from induction mediated by AhR ligands...
  33. pmc A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity
    C Masimirembwa
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
    Br J Clin Pharmacol 42:713-9. 1996
    ..We therefore postulate that the CYP2D6*17 allele might contribute to the molecular basis of the previously established diminished debrisoquine hydroxylase activity in African Bantu populations...
  34. ncbi Oligomerization properties of ERp29, an endoplasmic reticulum stress protein
    S Mkrtchian
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
    FEBS Lett 431:322-6. 1998
    ..Dimerization of the protein is suggested to be advantageous for the protein binding potential of ERp29...
  35. ncbi Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism
    C Rodriguez-Antona
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden
    Pharmacogenomics J 8:268-77. 2008
    ..In conclusion, two novel common CYP2C8 haplotypes were identified and significantly associated with altered rate of CYP2C8-dependent drug metabolism in vitro and in vivo...
  36. ncbi Implications of polymorphic cytochrome p450-dependent drug metabolism for drug development
    M Ingelman-Sundberg
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Drug Metab Dispos 29:570-3. 2001
    ..The alternative, however, of using the patient's genotype as a basis for individualized drug treatment constitutes, in light of rapid methodological developments, a very feasible approach to safer and more efficient drug therapies...
  37. ncbi Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy
    M Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 250:186-200. 2001
    ..Some emphasis will be given to different forms of cytochrome P450 which are of importance for drug metabolism...
  38. doi CNVs of human genes and their implication in pharmacogenetics
    I Johansson
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Cytogenet Genome Res 123:195-204. 2008
    ..In the current overview we provide an update of the situation with emphasis on clinically important examples...
  39. ncbi Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes
    M Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institute, Institute of Environmental Medicine, Box 210, 17177 Stockholm, Sweden
    Mutat Res 482:11-9. 2001
    ..In the present contribution, an overview is presented about our present knowledge about the polymorphism of xenobiotic metabolising CYPs and the importance for adverse effects of drugs and metabolic activation of xenobiotics...
  40. ncbi Thioredoxin fold as homodimerization module in the putative chaperone ERp29: NMR structures of the domains and experimental model of the 51 kDa dimer
    E Liepinsh
    Department of Medical Biochemistry and Biophysics, Karolinska Institute, 171 77, Stockholm, Sweden
    Structure 9:457-71. 2001
    ..ERp29 self-associates into 51 kDa dimers and also higher oligomers...
  41. ncbi The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent
    Barbara M A Lussenburg
    LACDR Division of Molecular Toxicology, Department of Pharmacochemistry, Vrije Universiteit, HV Amsterdam, The Netherlands
    Biochem Pharmacol 70:1253-61. 2005
    ..The presented data show that next to F120, residue F483 plays a very important role in the metabolism of typical CYP2D6 substrates. The influence of F483 on metabolism was found to be strongly substrate-dependent...
  42. ncbi Effects of diet and ethanol on the expression and localization of cytochromes P450 2E1 and P450 2C7 in the colon of male rats
    R Hakkak
    Department of Pediatrics and Pathology, University of Arkansas for Medical Sciences, Arkansas Children s Hospital Research Institute, Little Rock 72205, USA
    Biochem Pharmacol 51:61-9. 1996
    ..These results may provide a partial explanation for the mechanism underlying effects of diet and ethanol on colon cancer...
  43. ncbi The importance of residues in substrate recognition site 3 for the catalytic function of CYP2D25 (vitamin D 25-hydroxylase)
    F Hosseinpour
    Division of Biochemistry, Department of Pharmaceutical Biosciences, University of Uppsala, Uppsala, SE-751 23, Sweden
    Biochem Biophys Res Commun 288:1059-63. 2001
    ..The results implicate that residues in SRS-3 of CYP2D25 are important determinants for its function in vitamin D(3) metabolism...
  44. ncbi Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides
    J Bylund
    Division of Biochemical Pharmacology, Department of Pharmaceutical Biosciences, Uppsala Biomedical Centre, Uppsala University, SE 751 24 Uppsala, Sweden
    J Biol Chem 275:21844-9. 2000
    ..CYP4F8 is the first described hydroxylase with specificity and catalytic competence for prostaglandin endoperoxides...
  45. ncbi Cytochrome P450 pharmacogenetics and cancer
    C Rodriguez-Antona
    Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Center CNIO, Madrid, Spain
    Oncogene 25:1679-91. 2006
    ..This review gives an up-to-date description of our current knowledge in these areas...
  46. ncbi Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma
    C Rodriguez-Antona
    Departamento de Bioquimica, Facultad de Medicina, Universidad de Valencia, Valencia, Spain
    Mol Pharmacol 63:1180-9. 2003
    ..These findings revealed that C/EBP alpha and HNF-3 gamma cooperatively regulate CYP3A4 expression in hepatic cells by a mechanism that probably involves chromatin remodeling...
  47. ncbi Metabolic gene polymorphism frequencies in control populations
    S Garte
    Environmental and Occupational Health Sciences Institute, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854, USA
    Cancer Epidemiol Biomarkers Prev 10:1239-48. 2001
    ..No examples of linkage disequilibrium between the different loci were detected based on comparison of observed and expected frequencies for combinations of specific alleles...